Signorell J, Hunziker T, Martinelli M, Koestner S C, Mohacsi P J
Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern, Bern, Switzerland.
Transplant Proc. 2010 Nov;42(9):3871-5. doi: 10.1016/j.transproceed.2010.07.090.
Non-melanoma skin cancers (NMSCs) are the most common malignancies after solid organ transplantation. Their incidence increases with time after transplantation. Calcineurin-inhibitors (CNIs) and azathioprine are known as skin neoplasia-initiating and -enhancing immunosuppressants. In contrast, increasing clinical experience suggests a relevant antiproliferative effect of mammalian target of rapamycin inhibitors, also named proliferation signal inhibitors (PSIs). We report the case of a cardiac allograft recipient with an impressive and consolidated reduction of recurrent NMSC, observed after conversion from CNI-therapy to a PSI-based protocol.
非黑色素瘤皮肤癌（NMSCs）是实体器官移植后最常见的恶性肿瘤。其发病率随移植后的时间增加而上升。钙调神经磷酸酶抑制剂（CNIs）和硫唑嘌呤是已知的引发和促进皮肤肿瘤形成的免疫抑制剂。相比之下，越来越多的临床经验表明，雷帕霉素靶蛋白抑制剂（也称为增殖信号抑制剂，PSIs）具有显著的抗增殖作用。我们报告了一例心脏移植受者的病例，该患者在从CNI治疗转换为基于PSI的方案后，复发性NMSCs出现了显著且持续的减少。
